Daniel R. Hart

2023

In 2023, Daniel R. Hart earned a total compensation of $1.9M as Chief Financial Officer at Peregrine Pharmaceuticals, a 6% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$225,400
Salary$442,692
Stock Awards$1,217,152
Other$51,654
Total$1,936,898

Hart received $1.2M in stock awards, accounting for 63% of the total pay in 2023.

Hart also received $225.4K in non-equity incentive plan, $442.7K in salary and $51.7K in other compensation.

Rankings

In 2023, Daniel R. Hart's compensation ranked 544th out of 2,918 executives tracked by ExecPay. In other words, Hart earned more than 81.4% of executives.

ClassificationRankingPercentile
All
544
out of 2,918
81st
Division
Manufacturing
312
out of 1,608
81st
Major group
Chemicals And Allied Products
217
out of 901
76th
Industry group
Drugs
214
out of 864
75th
Industry
Pharmaceutical Preparations
134
out of 622
79th

Pay ratio

Daniel R. Hart's Pay$1,936,898
Median Employee's Pay$104,595
Pay Ratio

19

to 1

In 2023, the annual total compensation of Daniel R. Hart was $1,936,898.

The annual total compensation of the median employee at Peregrine Pharmaceuticals was $104,595.

The ratio of Daniel R. Hart's pay to the pay of median employee was therefore 19 to one.

Source: SEC filing on August 28, 2023.

Hart's colleagues

We found four more compensation records of executives who worked with Daniel R. Hart at Peregrine Pharmaceuticals in 2023.

2023

Nicholas Green

Peregrine Pharmaceuticals

Chief Executive Officer

2023

Mark Ziebell

Peregrine Pharmaceuticals

General Counsel

2023

Matthew Kwietniak

Peregrine Pharmaceuticals

Chief Commercial Officer

2023

Richard Richieri

Peregrine Pharmaceuticals

Chief Operations Officer

News

You may also like